HDAC-IN-46

HDAC-IN-46 (compound 12c) is a potent HDAC inhibitor with an IC50 value of 0.21 μM and 0.021 μM for HDAC1 and HDAC6, respectively. HDAC-IN-46 upregulates p-p38, and downregulates Bcl-xL and cyclin D1 in MDA-MB-231 cells. HDAC-IN-46 induces significant G2 phase arrest and apoptosis. HDAC-IN-46 can be used for researching triple-negative breast cancer (TNBC) [1].

Product Specifications

CAS Number

[2562386-85-8]

UNSPSC

12352005

Target

Apoptosis; HDAC

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/hdac-in-46.html

Solubility

10 mM in DMSO

Smiles

O=C(NO)CCCCCCCN1N=NC(C2=CC=C(C3=C(CC)N=C(N)N=C3N)C=C2)=C1

Molecular Formula

C22H30N8O2

Molecular Weight

438.53

References & Citations

[1]Wu B, et al. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity. Bioorg Med Chem. 2020 Mar 15;28 (6) :115345.